Ind-Swift Laboratories Limited (INDSWFTLAB) - Net Assets

Latest as of September 2025: Rs13.07 Billion INR ≈ $141.39 Million USD

Based on the latest financial reports, Ind-Swift Laboratories Limited (INDSWFTLAB) has net assets worth Rs13.07 Billion INR (≈ $141.39 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs15.44 Billion ≈ $167.02 Million USD) and total liabilities (Rs2.37 Billion ≈ $25.63 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Ind-Swift Laboratories Limited tangible equity quality to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Rs13.07 Billion
% of Total Assets	84.66%
Annual Growth Rate	9.98%
5-Year Change	94.39%
10-Year Change	126.69%
Growth Volatility	20.25

Ind-Swift Laboratories Limited - Net Assets Trend (2006–2025)

This chart illustrates how Ind-Swift Laboratories Limited's net assets have evolved over time, based on quarterly financial data. See Ind-Swift Laboratories Limited defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Ind-Swift Laboratories Limited (2006–2025)

The table below shows the annual net assets of Ind-Swift Laboratories Limited from 2006 to 2025. For live valuation and market cap data, see INDSWFTLAB market cap overview.

Year	Net Assets	Change
2025-03-31	Rs11.73 Billion ≈ $126.85 Million	+44.44%
2024-03-31	Rs8.12 Billion ≈ $87.82 Million	+19.08%
2023-03-31	Rs6.82 Billion ≈ $73.75 Million	+13.49%
2022-03-31	Rs6.01 Billion ≈ $64.98 Million	-0.42%
2021-03-31	Rs6.03 Billion ≈ $65.26 Million	-5.81%
2020-03-31	Rs6.41 Billion ≈ $69.28 Million	+8.99%
2019-03-31	Rs5.88 Billion ≈ $63.57 Million	+6.25%
2018-03-31	Rs5.53 Billion ≈ $59.83 Million	+4.13%
2017-03-31	Rs5.31 Billion ≈ $57.46 Million	+2.69%
2016-03-31	Rs5.17 Billion ≈ $55.96 Million	-12.97%
2015-03-31	Rs5.95 Billion ≈ $64.30 Million	-18.02%
2014-03-31	Rs7.25 Billion ≈ $78.43 Million	-15.02%
2013-03-31	Rs8.53 Billion ≈ $92.30 Million	+5.15%
2012-03-31	Rs8.12 Billion ≈ $87.78 Million	+39.10%
2011-03-31	Rs5.84 Billion ≈ $63.10 Million	+30.17%
2010-03-31	Rs4.48 Billion ≈ $48.48 Million	+23.46%
2009-03-31	Rs3.63 Billion ≈ $39.27 Million	+8.90%
2008-03-31	Rs3.33 Billion ≈ $36.06 Million	+7.05%
2007-03-31	Rs3.11 Billion ≈ $33.68 Million	+61.96%
2006-03-31	Rs1.92 Billion ≈ $20.80 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Ind-Swift Laboratories Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 137538500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (March 2025)

Component	Amount	Percentage
Common Stock	Rs687.44 Million	5.86%
Other Components	Rs12.42 Billion	105.86%
Total Equity	Rs11.73 Billion	100.00%

Ind-Swift Laboratories Limited Competitors by Market Cap

The table below lists competitors of Ind-Swift Laboratories Limited ranked by their market capitalization.

Company	Market Cap
Immunic Inc NASDAQ:IMUX	$158.42 Million
Acme United Corporation NYSE MKT:ACU	$158.51 Million
Ilyang Pharm KO:007570	$158.52 Million
Oando PLC JSE:OAO	$158.56 Million
Pinago Utama Tbk Pt JK:PNGO	$158.39 Million
Prospect Resources Ltd AU:PSC	$158.39 Million
MAX Automation SE XETRA:MXHN	$158.37 Million
Quanterix Corp NASDAQ:QTRX	$158.35 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Ind-Swift Laboratories Limited's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 9,361,773,000 to 11,729,997,000, a change of 2,368,224,000 (25.3%).
Net income of 2,504,766,000 contributed positively to equity growth.
Share repurchases of 926,341,000 reduced equity.
New share issuances of 926,341,000 increased equity.
Other comprehensive income decreased equity by 1,781,325,000.
Other factors increased equity by 1,644,783,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	Rs2.50 Billion	+21.35%
Share Repurchases	Rs926.34 Million	-7.9%
Share Issuances	Rs926.34 Million	+7.9%
Other Comprehensive Income	Rs-1.78 Billion	-15.19%
Other Changes	Rs1.64 Billion	+14.02%
Total Change	Rs-	25.30%

Book Value vs Market Value Analysis

This analysis compares Ind-Swift Laboratories Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 0.85x
The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
The price-to-book ratio has decreased from 1.79x to 0.85x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2006-03-31	Rs94.11	Rs168.68	x
2007-03-31	Rs138.71	Rs168.68	x
2008-03-31	Rs142.55	Rs168.68	x
2009-03-31	Rs137.63	Rs168.68	x
2010-03-31	Rs160.53	Rs168.68	x
2011-03-31	Rs181.90	Rs168.68	x
2012-03-31	Rs221.52	Rs168.68	x
2013-03-31	Rs215.88	Rs168.68	x
2014-03-31	Rs177.05	Rs168.68	x
2015-03-31	Rs147.96	Rs168.68	x
2016-03-31	Rs126.31	Rs168.68	x
2017-03-31	Rs124.86	Rs168.68	x
2018-03-31	Rs122.76	Rs168.68	x
2019-03-31	Rs110.54	Rs168.68	x
2020-03-31	Rs129.52	Rs168.68	x
2021-03-31	Rs102.14	Rs168.68	x
2022-03-31	Rs101.71	Rs168.68	x
2023-03-31	Rs115.41	Rs168.68	x
2024-03-31	Rs158.43	Rs168.68	x
2025-03-31	Rs198.52	Rs168.68	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Ind-Swift Laboratories Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 21.35%
The company demonstrates strong efficiency in generating profits from shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 44.59%
• Asset Turnover: 0.39x
• Equity Multiplier: 1.23x
Recent ROE (21.35%) is above the historical average (4.58%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2006	17.42%	10.65%	0.61x	2.67x	Rs142.64 Million
2007	5.86%	5.21%	0.50x	2.24x	Rs-129.07 Million
2008	9.42%	6.86%	0.57x	2.42x	Rs-19.21 Million
2009	11.12%	6.84%	0.61x	2.64x	Rs40.82 Million
2010	12.58%	7.18%	0.62x	2.84x	Rs115.59 Million
2011	15.48%	8.53%	0.60x	3.01x	Rs316.51 Million
2012	10.82%	6.33%	0.64x	2.68x	Rs67.86 Million
2013	-13.81%	-10.38%	0.48x	2.78x	Rs-2.03 Billion
2014	-16.82%	-12.64%	0.42x	3.20x	Rs-1.95 Billion
2015	-19.69%	-18.07%	0.29x	3.70x	Rs-1.80 Billion
2016	-11.34%	-8.98%	0.29x	4.29x	Rs-1.10 Billion
2017	-7.37%	-5.61%	0.33x	4.02x	Rs-922.67 Million
2018	3.97%	2.87%	0.38x	3.66x	Rs-333.48 Million
2019	4.79%	3.83%	0.39x	3.19x	Rs-314.47 Million
2020	-3.31%	-2.72%	0.42x	2.92x	Rs-852.52 Million
2021	-0.52%	-0.35%	0.49x	3.01x	Rs-634.98 Million
2022	-0.36%	-0.21%	0.58x	3.00x	Rs-622.46 Million
2023	6.98%	3.94%	0.66x	2.67x	Rs-205.96 Million
2024	44.97%	32.86%	0.88x	1.56x	Rs3.27 Billion
2025	21.35%	44.59%	0.39x	1.23x	Rs1.33 Billion

Industry Comparison

This section compares Ind-Swift Laboratories Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $41,118,163,484
Average return on equity (ROE) among peers: 13.86%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Ind-Swift Laboratories Limited (INDSWFTLAB)	Rs13.07 Billion	17.42%	0.18x	$158.41 Million
Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS)	$366.97 Million	3.51%	2.41x	$25.11 Million
Aarti Drugs Limited (AARTIDRUGS)	$1.23 Billion	12.93%	2.27x	$365.36 Million
Aarti Pharmalabs Limited (AARTIPHARM)	$2.31 Million	-8.08%	0.08x	$645.54 Million
Abbott India Limited (ABBOTINDIA)	$2.31 Billion	29.62%	0.43x	$6.01 Billion
Ajanta Pharma Limited (AJANTPHARM)	$32.64 Billion	21.83%	0.24x	$4.15 Billion
Akums Drugs and Pharmaceutical (AKUMS)	$7.23 Billion	13.11%	3.52x	$996.26 Million
Alkem Laboratories Limited (ALKEM)	$75.58 Billion	20.97%	0.52x	$6.95 Billion
Amrutanjan Health Care Limited (AMRUTANJAN)	$1.09 Billion	18.92%	0.29x	$170.62 Million
Alembic Pharmaceuticals Limited (APLLTD)	$22.20 Billion	18.58%	0.77x	$1.59 Billion
Aurobindo Pharma Limited (AUROPHARMA)	$268.52 Billion	7.18%	0.49x	$8.98 Billion

About Ind-Swift Laboratories Limited

NSE:INDSWFTLAB India Drug Manufacturers - Specialty & Generic

Market Cap

$158.41 Million

Rs14.65 Billion INR

Market Cap Rank

#17535 Global

#914 in India

Share Price

Rs168.68

Change (1 day)

+3.82%

52-Week Range

Rs88.15 - Rs168.68

All Time High

Rs176.72